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Aim:  This study  was  undertaken  to  compare  the  immunogenicity  of  a three  dose  and  ﬁve dose  schedule
of an  oral  live-attenuated  human  rotavirus  vaccine,  Rotarix® in south  Indian  infants.
Method: Healthy  infants  (N =  90),  six  to seven  weeks  of  age  were  enrolled  to  receive  three  doses  (n  =  45)
or  ﬁve  doses  of  Rotarix  vaccine  (n = 45)  along  with  other  scheduled  vaccines,  each  dose  separated  by  a
four  week  interval.  Blood  samples  were  taken  before  vaccination  and  one  month  post-dose  three  in the
Rotarix  three  dose  group  and  one  month  post-dose  ﬁve  in  the  Rotarix  ﬁve  dose  group; all  were  tested  for
anti-rotavirus  IgA by  an  antibody  sandwich  enzyme  immunoassay.
Results:  At  baseline,  >50%  of infants  had  >20 units  of anti-rotavirus  IgA. The  seroconversion  rates  after
three  and  ﬁve doses  were  low  and  not  signiﬁcantly  different  in  the  two  groups.  However,  among  vaccine
responders,  children  seropositive  at  baseline  showed  a much  greater  absolute  increase  in IgA antibody
levels  than children  seronegative  at baseline.
Conclusions:  Rotarix  vaccine  showed  low  immunogenicity  in south  Indian  children  and  increasing  the
number  of doses  did  not  increase  the  proportion  of infants  seroconverting  after  vaccination.
©  2014  Published  by Elsevier  Ltd.  This  is an  open  access  article  under the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Rotaviruses, the primary etiological agents of severe gastroen-
eritis in children less than ﬁve years of age, cause more pediatric
iarrhea-related deaths than any other agent in low and middle-
ncome countries [1]. Although universal in childhood, rotavirus
nfections occur earlier in the developing world [2–4]. First infec-
ions, though often severe, have been shown to induce immunity
gainst subsequent infections. Vaccination with an oral vaccine
s intended to mimic  infections that result in protection without
ausing illness [4,5].
Two oral rotavirus vaccines are currently licensed in over
00 countries for infants six weeks of age and older. Rotarix, an
ttenuated G1P[8] human strain (89-12), is administered as a two-
ose series [6]. Rotateq, containing ﬁve bovine-human reassortant
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264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC Bstrains with G1, G2, G3, G4, and P[8] human surface antigens, is
administered as a three-dose series [6]. The World Health Organiza-
tion (WHO) has recommended the introduction of these vaccines in
national immunization programs worldwide, after review of clini-
cal trial data from Africa and Asia, and post licensure data from the
Americas [7].
The protective efﬁcacy of the rotavirus vaccine, likely involv-
ing mucosal (intestinal) and systemic antibody responses as well
as the cell-mediated immune system, is higher than expected from
serum IgA measurements in some ﬁeld trials, where seroconversion
rates were lower than efﬁcacy [8]. Although there is no recognized
correlate of protection at the individual level, serum anti-RV IgA
antibodies are generally accepted as a marker of vaccine immuno-
genicity and a possible surrogate of protection at the level of the
general community [9].
Well documented evidence shows that immunogenicity and
efﬁcacy of most oral vaccines in developing countries is lower than
in developed countries, in all age groups [10]. Recent studies also
show that seroconversion and efﬁcacy rates of rotavirus vaccines
in low and middle-income countries in Asia and Africa [11–13]
are much lower than in the United States of America, Europe,
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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igh-income Asian and Latin American countries [14–18]. Further,
accine efﬁcacy declines signiﬁcantly in developing countries in the
econd year of assessment [19].
The present study was  conducted to compare three and ﬁve
oses of an oral rotavirus vaccine for immunogenicity to determine
hether increasing the number of doses increases the proportion
f children responding to the vaccine, similar to the phenomenon
bserved in developing countries with the oral polio vaccine (OPV)
20].
. Materials and methods
.1. Study design and participants
This phase IV randomized, parallel group comparison study was
onducted in the Well Baby Clinic of Christian Medical College
CMC) in Vellore, south India between March and December 2012.
he study protocol was approved by the CMC  Institutional Review
oard and the trial was registered with the Clinical Trials Registry
f India (CTRI/2012/02/002454).
Healthy term infants with a birth weight ≥2 kg aged less than
even weeks attending the Well Baby Clinic at CMC  Vellore for rou-
ine immunization were invited to participate in the study. Infants
ere not eligible for the study if they had received an experimental
otavirus vaccine prior to the study, suffered from any congeni-
al or chronic gastrointestinal diseases including any uncorrected
ongenital malformation of the gastrointestinal tract, received any
mmunosuppressant or immunoglobulin, or had a history of gas-
roenteritis seven days prior to their visit. The purpose of the study
nd the procedures were explained and signed informed consent
as obtained from the parents or legal guardians. Enrolled chil-
ren were randomized to receive three or ﬁve doses at six, 10 and
4 weeks or at six, 10, 14, 18 and 22 weeks respectively, along with
cheduled childhood vaccines, based on randomization codes pro-
ided by a biostatistician not connected with the study as serially
umbered opaque sealed envelopes.
All routine vaccines were administered as per the National
mmunization Schedule or the Indian Academy of Paediatrics
chedule at six-10-14 weeks of age (i.e., DTPw/DTap, Haemophilus
nﬂuenza type b, OPV/IPV and, Hepatitis B) [21], followed by the
otarix vaccination at six, 10 and 14 weeks, and in the ﬁve dose
rm two additional doses at 18 and 22 weeks.
.2. Immunogenicity assessment
Two blood samples of 3.5 ml  were collected from all infants,
he ﬁrst prior to the administration of the ﬁrst dose of Rotarix
accine and the second 28 days after the last (third or ﬁfth)
ose of vaccine administration. Each sample was analyzed for
otavirus speciﬁc IgA by an antibody-sandwich enzyme immunoas-
ay which has been validated by the same laboratory that carried
ut pre-licensure vaccine evaluations for several vaccines [22].
rieﬂy, 96 well microtiter plates were coated overnight with serum
rom rabbits hyper-immunized with puriﬁed double-layered SA11
erived rotavirus particles. The next day, partially puriﬁed cell
ulture lysates derived from G1P8 (RIX4414) infected or mock-
nfected MA  104 cells were added. Dilutions of a standard pool
f human serum assigned an arbitrary value of 1000 U or test
era were added followed by the addition of biotinylated rabbit
nti-human IgA, peroxidase-conjugated avidin-biotin, and sub-
trate (orthophenylenediamine/H2O2). After 30 min, the reaction
as stopped with 1 M H2SO4, and absorbance was read at 492 nm.
he IgA titer was determined by comparing the optical density val-
es from sample wells with the standard curve based on derived 32S (2014) A129–A133
units of IgA arbitrarily assigned to a pooled human serum samples,
as previously described [22].
Seropositivity was  deﬁned as an anti-rotavirus IgA concentra-
tion ≥20 U/ml. Seroconversion was considered as the presence of
≥20 U/ml anti-rotavirus IgA in infants who  were negative for anti-
RV IgA prior to vaccination. A cut-off of 20 RV-IgA units [11], or
at least twofold changes in case of a higher baseline values. Sero-
conversion rate and geometric mean concentrations (GMCs) were
assessed at one month after dose three or dose ﬁve of Rotarix
administration.
2.3. Sample size and statistical analysis
Sample size for enrollment was calculated based on an expected
seroconversion of 60% with three doses, which was  expected to
increase to 75% with ﬁve doses. The expected seroconversion was
based on published data with Rotarix vaccine, which showed 58%
seroconversion in Indian children given two  doses of vaccine at
eight and 12 weeks of age [23].
Variables were assessed using descriptive statistics, dispersion
for continuous variables, frequency counts and marginal per-
centages with 95% conﬁdence intervals for categorical variables.
Comparisons between the two  groups were done using t-tests for
normally distributed variables (or non-parametric tests for non-
normally distributed variables) and chi-square tests for categorical
variables. All differences were considered statistically signiﬁcant if
the two-tailed p-value was  <0.05.
3. Results
A total of 118 infants were assessed for enrollment and 28
infants (ﬁve did not meet the inclusion criteria, 17 refused par-
ticipation, six were unavailable for the follow up period) were
excluded. Of the 90 infants who were enrolled, 45 were random-
ized into the three dose arm and 45 into the ﬁve-dose arm (Fig. 1).
Demographic details for infants recruited in both arms of the study
were similar (data not shown) and all children received the vaccine
by 17 and 26 weeks of age in the three and ﬁve dose arms, respec-
tively. Sera at 4 weeks post third and ﬁfth dose were obtained from
88 of 90 infants, with one child lost to follow up in each arm.
Of the enrolled infants, 66% (29/44 infants) from the three dose
group and 50% (22/44) infants from the ﬁve dose group were
seropositive at baseline (Fig. 2). Of the 51 infants seropositive
prior to immunization, 13 (25.5%) showed a >4 fold and 12 (23.5%)
showed a three or two fold increase in RV speciﬁc IgA four weeks
post last dose of vaccination; 26 (51%) infants did not show any rise
or fall in antibody levels. Of the 37 infants who  were seronegative
at baseline, 10 (27%) had a >4-fold and seven (19%) had a three or
two fold increase in RV speciﬁc IgA. Twenty (54%) infants had no
rise or fall in antibody levels and remained seronegative even after
three or ﬁve doses of vaccination.
The GMCs of IgA pre- and post-vaccination are shown in Table 1,
stratiﬁed by baseline seropositivity in the three and ﬁve dose arms.
The Wilcoxon signed rank test showed that there was  a signiﬁcant
difference (p-value < 0.001) between the pre- and post-vaccination
GMCs of the 88 infants taken together and separately as the three
dose arm (p = 0.029) and the ﬁve dose arm (p < 0.001). However,
with three doses, in baseline seropositive children the difference
between pre- and post-GMCs did not reach statistical signiﬁcance
(p = 0.086). Of the 88 infants, 42 (47.7%) responded to three or ﬁve
doses of vaccination. When the proportion of children seroconvert-
ing and the GMCs were compared between the three and ﬁve dose
arms (Tables 2A and 2B), there was no signiﬁcant difference in the
post vaccination rotavirus speciﬁc serum IgA levels between them
(p-value = 0.894, Mann–Whitney 0.894U test).
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iFig. 1. Schematic diagram of a phase 4, randomized trial comparing
However among responders, children who were seropositive at
aseline showed a much larger increase in the amount of antibody
han children who were initially seronegative. Children seropos-
tive at baseline who received and responded to three doses of
Fig. 2. Immune response in Indian infants gmunogenicity of 3 and 5 doses of Rotarix vaccine in Indian infants.
vaccine and showed an at least twofold response, had GMCs >200;
while children seronegative at baseline who  responded to 5 doses
of vaccine and had a >4 fold response, had a GMC  of 83 units
(Tables 2A and 2B).
iven 3 and 5 doses of Rotarix vaccine.
A132 R.Z. Kompithra et al. / Vaccine 32S (2014) A129–A133
Table 1
Comparison of pre- and post-vaccination geometric mean concentrations of anti-rotavirus IgA in 88 Indian children randomized to receive 3 or 5 doses of Rotarix vaccine.
GMC  (95% CI) p valuea
Pre vaccination Post vaccination
Overall (n = 88) 24.0 (16.3–35.2) 58.0 (39.4–85.1) <0.001
Baseline seropositives (n = 51) 81.2 (60.1–109.7) 150.3 (105.1–215.7) 0.006
Baseline seronegatives (n = 37) 3.9 (2.5–5.8) 15.1 (8.5–26.3) <0.001
3  dose arm (n = 44) 25.5 (14.5–44.5) 53.7 (29.7–96.6) 0.029
3  dose – baseline seropositives (n = 29) 71.5 (48.6–105.0) 123.7 (77.9–195.9) 0.086
3  dose – baseline seronegatives (n = 15) 2.8 (0.9–6.5) 10.1 (2.6–33.3) 0.028
5  dose arm (n = 44) 22.6 (13.0–39.0) 62.5 (37.1–104.8) <0.001
5  dose – baseline seropositives (n = 22) 96.1 (57.7–159.6) 194.3 (107.7–349.3) 0.024
5  dose – baseline seronegatives (n = 22) 4.8 (3.0–7.3) 19.7 (12.3–33.8) < 0.001
a p-Values are obtained using Wilcoxon Signed Rank test (alpha = 0.05).
Table 2A
Seroresponse among 51 baseline seropositive infants given 3 or 5 doses of Rotarix vaccine.
Response Proportion GMC  (95% CI)
3 dose 5 dose p valuea 3 dose 5 dose p valueb
≥2-fold 15/29 10/22 0.657 234.4 (128.0–428.6) 442.5 (191.5–1020.8) 0.157
≥3-fold 9/29 8/22 0.689 307.3 (133.3–706.7) 477.1 (166.2–1366.4) 0.36
≥4-fold 8/29 5/22 0.693 366.2 (156.8–853.6) 536.2 (119.5–2394.4) 0.42
a p-Values are obtained using Chi square test (alpha = 0.05).
b p-Values are obtained using Mann–Whitney U test (alpha = 0.05).
Table 2B
Seroresponse among 37 baseline seronegative infants to 3 or 5 doses of Rotarix vaccine.
Response Proportion GMC  (95% CI)
3 dose 5 dose p valuea 3 dose 5 dose p valueb
<20 to >20 U 7/15 10/22 0.944 72.9(30.9–172.3) 60 (35.3–102.2) 0.625
≥4-fold 5/15 5/22 0.477 106.2(38.3–294.6) 82.7 (24.5–279.9) 0.602
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. Discussion
Most vaccine studies worldwide with Rotarix have measured
ntibody titer at baseline and after two doses. In this study, a
igh baseline seropositivity was found with 51/88 (57.9%) of the
ecruited healthy infants aged six weeks having ≥20 U of RV serum
gA at baseline. We  have previously reported detection of rotavirus
n 43.9% of 1411 hospitalized neonates in Vellore in south India,
ncluding those with and without gastrointestinal disease [24]. In
 community-based study from Vellore, rotavirus infections were
etected in about 56% of children by about six months of age
25]. The high baseline IgA rates in this study appear to indi-
ate that hospital-born children where rates of neonatal infection
ith G10P[11] strains are high [24] do mount an IgA response
ost-infection, but the reason why there was a low response in
hildren given a vaccine based on a G1P[8] strain is unknown. A
re-licensure vaccine trial conducted in India for Rotarix observed
hat 27% of eight week old infants were initially seropositive; the
eroconversion rate observed one month after two  doses was  58.3%
95% CI: 48.7; 67.4) [23]. On the other hand, the study evaluating
mmunogenicity of Rotateq in India observed that 20% of 6–12 week
ld infants were seropositive at baseline and about 83% infants
emonstrated a three fold increase in anti rotavirus IgA titers from
aseline up to approximately six months post vaccination [26].
oth vaccine studies found comparatively higher levels of baseline
eropositivity, and lower seroconversion rates following vaccina-
ion than studies conducted in western countries, but not as low as
eported here. However, both vaccines have been licensed in Indiato be administered along with other EPI vaccines, starting at six
weeks of age.
Although 42/88 (47.7%) infants had a response to Rotarix vac-
cine (Tables 2A and 2B), there was  no signiﬁcant difference in
the proportion and GMC  of infants who  responded to three and
ﬁve doses of vaccination. No study has previously used ﬁve doses
of Rotarix, but two  studies from South-Africa [27] and Malawi
[28] have assessed two versus three doses. Data from these tri-
als showed higher although not signiﬁcant seroconversion rates
among the infants who  received three doses (66.7% in South African
infants and 57.1% in Malawian infants) versus two doses (57.1%
in South African infants and 47.2% in Malawian infants). A trend
toward higher GMCs was  observed in the three dose group (94.3 in
South African infants and 63 in Malawian infants) than the two  dose
group (59.4 in South African infants and 51.5 in Malawian infants).
Although neither study was powered to compare the two dos-
ing regimes, further results indicated that a threedose schedule of
Rotarix may  have an advantage in providing long-term protection
against severe RV gastroenteritis and severe all-cause gastroen-
teritis. It is interesting to note that in Malawi, only 17/126 (13.5%)
children had >20 U of RV IgA at baseline which is much lower than
reported here.
This study had several limitations, including the small sample
size, and the lack of collection of serum samples between doses.
It is possible that the timing of collection of serum samples may
have coincided with waning of the antibody response to the vaccine
following multiple doses, with an earlier peak response after the
ﬁrst or the second dose.
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Nonetheless, although baseline seropositivity made no differ-
nce to the rates of seroconversion, the increase in antibody
evels was much greater in baseline seropositive infants in both
rms. Those with prior natural infection had a much higher ini-
ial antibody level at baseline than was induced by vaccination
n unexposed children. Additionally, baseline seropositive children
howed much greater absolute increases than those without prior
atural infection, which could possibly be explained by higher and
ore robust responses being induced by natural infection than vac-
ination or by as yet undiscovered biological differences between
esponders and non-responders.
Given that high baseline seropositivity rates indicate ongoing
xposure, measuring serum RV-IgA levels after a full course of
accination may  be uninformative. Studies with more frequent
ampling might result in a better understanding of the immune
esponse to oral rotavirus vaccines, but these studies are difﬁcult
o do because of the young age of children receiving vaccine and the
eed for frequent blood sampling. Overall, it is a signiﬁcant concern
hat the seroresponses with Rotarix are much lower than reported
n a previous bridging study in India [29], but the bridging study
dministered the vaccine at older ages (e.g., eight and 12 weeks)
nd without concomitant administration of OPV which has been
hown to interfere with the rotavirus vaccine response. Based on
he studies conducted mainly in Latin America, it appeared that
otavirus vaccines did not affect immune responses to OPV, but IgA
ntibody levels following rotavirus vaccination were lower when
otavirus vaccines were co-administered with OPV. Data suggested
hat the interference was greater after the ﬁrst dose of OPV, and was
vercome with subsequent rotavirus vaccine doses [29].
However, it is possible that in developing country settings, the
nterference may  be greater than has been recognized so far, under-
coring the need for further studies to understand the immune
esponse to rotavirus vaccines and the functional consequences of
esponse and non-response.
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